

## Company Focus

31 October 2007 | 14 pages

# Nestle India (NEST.BO)

 Change in opinion   
 Rating change   
 Target price change   
 Estimate change   
 Results 

## Downgrade to Sell: 3Q07 – Great Run, But Valuations Catch Up

- Valuations factor in growth** — Nestle has had a great run and is up 52% over the last 6 months, outperforming our Indian consumer universe by 30%; it is trading at 29x08E P/E, at the higher end of its historical trading band. Valuations have caught up with fundamentals, capturing the strong growth profile that Nestle offers. Downgrading our rating to Sell (3L) from Buy (1L).
- Less expensive plays available** — We prefer less expensive F&B names like GSK Consumer, Britannia and Tata Tea to play the F&B margin turnaround in India. While we do not undermine Nestlé's superior profitability, brand strength and product width, its premium valuations already capture this. Other F&B names in our universe are trading between 42%-60% discount to Nestlé's valuations and offer relatively stronger earnings growth.
- Strong 3Q07** — 3Q07 results were solid – sales grew 25.5% yoy, with domestic sales growing 30% yoy. Nestles' product extensions are driving strong growth, which we expect to continue. In addition, the company has been able to defy raw material cost pressures through price hikes; EBITDA margins in 3Q increased by 140bps, while net profit increased 37% yoy.
- Revising estimates, price target** — Revising EPS estimates for Nestle, tweaking assumptions following 9m07 results. We cut 2007E-09E EPS estimates by 6.9%-2.8%. However, we raise our target price to Rs1341, as we roll forward our 25x P/E target multiple to Dec-08. Despite our TP increase, there is still 12% downside to the stock price from current levels.

|                              |               |
|------------------------------|---------------|
| <b>Sell/Low Risk</b>         | <b>3L</b>     |
| <i>from Buy/Low Risk</i>     |               |
| Price (31 Oct 07)            | Rs1,562.75    |
| Target price                 | Rs1,341.00    |
| <i>from Rs1,244.00</i>       |               |
| Expected share price return  | -14.2%        |
| Expected dividend yield      | 2.0%          |
| <b>Expected total return</b> | <b>-12.1%</b> |
| Market Cap                   | Rs150,674M    |
|                              | US\$3,830M    |

### Price Performance (RIC: NEST.BO, BB: NEST IN)



### Statistical Abstract

| Year to | Net Profit | Diluted EPS | EPS growth | P/E  | P/B  | ROE   | Yield |
|---------|------------|-------------|------------|------|------|-------|-------|
| 31 Dec  | (RsM)      | (Rs)        | (%)        | (x)  | (x)  | (%)   | (%)   |
| 2005A   | 3,096      | 32.11       | 22.9       | 48.7 | 42.5 | 91.9  | 1.6   |
| 2006A   | 3,151      | 32.68       | 1.8        | 47.8 | 38.7 | 84.8  | 1.6   |
| 2007E   | 4,020      | 41.70       | 27.6       | 37.5 | 34.0 | 96.7  | 2.0   |
| 2008E   | 5,175      | 53.68       | 28.7       | 29.1 | 26.5 | 102.3 | 2.3   |
| 2009E   | 6,014      | 62.38       | 16.2       | 25.1 | 21.8 | 95.5  | 2.8   |

Source: Powered by dataCentral

### Princy Singh<sup>1</sup>

 +91-22-6631-9871  
 princy.singh@citi.com

### Pragati Khadse<sup>1</sup>

 +91-22-6631-9856  
 pragati.khadse@citi.com

### Aditya Mathur<sup>1</sup>

aditya.mathur@citi.com

See Appendix A-1 for Analyst Certification and important disclosures.

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

<sup>1</sup>Citigroup Global Markets India Private Limited

| Fiscal year end 31-Dec                   | 2005          | 2006          | 2007E         | 2008E         | 2009E         |
|--|---------------|---------------|---------------|---------------|---------------|
| <b>Valuation Ratios</b>                  |               |               |               |               |               |
| P/E adjusted (x)                         | 48.7          | 47.8          | 37.5          | 29.1          | 25.1          |
| EV/EBITDA adjusted (x)                   | 28.6          | 27.7          | 22.8          | 18.0          | 15.4          |
| P/BV (x)                                 | 42.5          | 38.7          | 34.0          | 26.5          | 21.8          |
| Dividend yield (%)                       | 1.6           | 1.6           | 2.0           | 2.3           | 2.8           |
| <b>Per Share Data (Rs)</b>               |               |               |               |               |               |
| EPS adjusted                             | 32.11         | 32.68         | 41.70         | 53.68         | 62.38         |
| EPS reported                             | 32.11         | 32.68         | 41.70         | 53.68         | 62.38         |
| BVPS                                     | 36.73         | 40.33         | 45.93         | 58.98         | 71.71         |
| DPS                                      | 25.00         | 25.50         | 32.00         | 36.00         | 44.00         |
| <b>Profit &amp; Loss (RsM)</b>           |               |               |               |               |               |
| Net sales                                | 24,769        | 28,161        | 34,630        | 40,788        | 46,545        |
| Operating expenses                       | -20,117       | -23,439       | -28,836       | -33,312       | -37,809       |
| <b>EBIT</b>                              | <b>4,652</b>  | <b>4,722</b>  | <b>5,793</b>  | <b>7,476</b>  | <b>8,735</b>  |
| Net interest expense                     | -2            | -4            | -7            | -7            | -7            |
| Non-operating/exceptionals               | 41            | 88            | 250           | 301           | 301           |
| <b>Pre-tax profit</b>                    | <b>4,691</b>  | <b>4,805</b>  | <b>6,036</b>  | <b>7,770</b>  | <b>9,029</b>  |
| Tax                                      | -1,595        | -1,654        | -2,016        | -2,595        | -3,015        |
| Extraord./Min.Int./Pref.div.             | 0             | 0             | 0             | 0             | 0             |
| <b>Reported net income</b>               | <b>3,096</b>  | <b>3,151</b>  | <b>4,020</b>  | <b>5,175</b>  | <b>6,014</b>  |
| Adjusted earnings                        | 3,096         | 3,151         | 4,020         | 5,175         | 6,014         |
| Adjusted EBITDA                          | 5,220         | 5,385         | 6,531         | 8,218         | 9,501         |
| <b>Growth Rates (%)</b>                  |               |               |               |               |               |
| Sales                                    | 11.2          | 13.7          | 23.0          | 17.8          | 14.1          |
| EBIT adjusted                            | 15.8          | 1.5           | 22.7          | 29.0          | 16.8          |
| EBITDA adjusted                          | 15.8          | 3.2           | 21.3          | 25.8          | 15.6          |
| EPS adjusted                             | 22.9          | 1.8           | 27.6          | 28.7          | 16.2          |
| <b>Cash Flow (RsM)</b>                   |               |               |               |               |               |
| <b>Operating cash flow</b>               | <b>3,067</b>  | <b>3,808</b>  | <b>4,808</b>  | <b>5,803</b>  | <b>6,686</b>  |
| Depreciation/amortization                | 568           | 663           | 737           | 741           | 765           |
| Net working capital                      | -374          | 109           | 51            | -114          | -93           |
| <b>Investing cash flow</b>               | <b>-1,812</b> | <b>-738</b>   | <b>199</b>    | <b>-1,598</b> | <b>-1,886</b> |
| Capital expenditure                      | -1,000        | -1,242        | -68           | -400          | -400          |
| Acquisitions/disposals                   | -812          | 504           | 267           | -1,198        | -1,486        |
| <b>Financing cash flow</b>               | <b>-2,684</b> | <b>-2,784</b> | <b>-3,543</b> | <b>-3,916</b> | <b>-4,786</b> |
| Borrowings                               | 64            | 20            | -63           | 0             | 0             |
| Dividends paid                           | -2,748        | -2,803        | -3,481        | -3,916        | -4,786        |
| <b>Change in cash</b>                    | <b>-1,430</b> | <b>286</b>    | <b>1,464</b>  | <b>290</b>    | <b>14</b>     |
| <b>Balance Sheet (RsM)</b>               |               |               |               |               |               |
| <b>Total assets</b>                      | <b>10,637</b> | <b>11,932</b> | <b>12,734</b> | <b>14,870</b> | <b>16,931</b> |
| Cash & cash equivalent                   | 1,411         | 1,541         | 2,030         | 3,517         | 5,016         |
| Accounts receivable                      | 305           | 558           | 450           | 530           | 605           |
| Net fixed assets                         | 4,966         | 5,800         | 5,131         | 4,789         | 4,424         |
| <b>Total liabilities</b>                 | <b>7,096</b>  | <b>8,043</b>  | <b>8,306</b>  | <b>9,183</b>  | <b>10,016</b> |
| Accounts payable                         | 3,198         | 3,736         | 3,814         | 4,492         | 5,125         |
| Total Debt                               | 143           | 163           | 100           | 100           | 100           |
| <b>Shareholders' funds</b>               | <b>3,541</b>  | <b>3,889</b>  | <b>4,429</b>  | <b>5,687</b>  | <b>6,914</b>  |
| <b>Profitability/Solvency Ratios (%)</b> |               |               |               |               |               |
| EBITDA margin adjusted                   | 21.1          | 19.1          | 18.9          | 20.1          | 20.4          |
| ROE adjusted                             | 91.9          | 84.8          | 96.7          | 102.3         | 95.5          |
| ROIC adjusted                            | 152.7         | 120.9         | 140.1         | 189.5         | nm            |
| Net debt to equity                       | -35.8         | -35.5         | -43.6         | -60.1         | -71.1         |
| Total debt to capital                    | 3.9           | 4.0           | 2.2           | 1.7           | 1.4           |

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



## Valuations Catch Up With Fundamentals


**Figure 1 Nestle India: Absolute & Relative Performance to Sensex**

| (%)            | 3M | 6M | 12M |
|----------------|----|----|-----|
| Absolute       | 29 | 52 | 45  |
| Rel. to .BSESN | 1  | 6  | (5) |

Source: Powered by dataCentral

We downgrade our rating on Nestle from Buy (1L) to Sell (3L) following a strong 52% run in the stock price over the last 6 months. While Nestle is among the fastest growing F&B companies in our Indian consumer universe, we believe that valuations have now caught up with fundamentals and do not leave much scope for further upsides. The stock is trading at 29.1x08E P/E, which is at the higher end of its historical trading band. While we are cognizant of Nestlé's superior margins, capital efficiency and brand strength, we believe that is already being captured in its premium valuations, and we do not see any further reasons that warrant a valuation multiple re-rating on the stock. We therefore maintain our 25x target P/E multiple, though we increase our price target to Rs1341 from Rs1244 earlier as we roll forward our target P/E from Jun-08 to Dec-08. We are already in 4Q07 and expect the stock valuations to increasingly start reflecting Dec-08 earnings estimates.


**Figure 2. Nestle P/E Bands**



Source: DataStream; Citi Investment Research

## Less Expensive F&B Plays Available

Figure 3. Nestle PE relative to Consumer PE



Source: Citi Investment Research

We advocate investors to look at less expensive F&B plays that are available in our Indian Consumer universe. We would like to concede up front that Nestle offers the best brand profile and width of products compared with the other F&B plays in our universe. However, we also attribute a premium to Nestle to account for its relatively better positioning, and we believe that currently Nestlé's valuation gap vs. peers has increased substantially. Nestlé's stock has strongly outperformed the CIR India consumer universe average, and its current valuation premium to the sector is at a historically high level. As such, we believe that from a risk-return perspective, there are other plays available in the Indian F&B space.

Our picks in the Indian F&B space would be GSK Consumer, Britannia and Tata Tea (though Tata Tea is not strictly a pure Indian play). Indian F&B companies offer strong sales growth and are also at the cusp of a margin turnaround that will accelerate near-term earnings growth. Currently, these stocks are trading at 42%-60% valuation discount to Nestlé's valuations, and we believe offer superior risk-return profiles compared with Nestle.

Please see our recent notes on these companies for more details. The links to these are appended below (no password required)

Britannia: <https://www.citigroupgeo.com/pdf/SAP10323.pdf>

GSK Consumer: <https://www.citigroupgeo.com/pdf/SAP10338.pdf>


Tata Tea: <https://www.citigroupgeo.com/pdf/SAP10565.pdf>

Figure 4. Food & Beverages Valuations

| Company              | RIC Code | Rating | Mkt Cap (LCM) | Target Price | P/E (x)     |             | EV/EBITDA (x) |            | Dvd Yield (%) | RoE (%)      | RoCE (%)     | EPS CAGR    |
|----------------------|----------|--------|---------------|--------------|-------------|-------------|---------------|------------|---------------|--------------|--------------|-------------|
|                      |          |        |               |              | 2008        | 2009        | 2008          | 2009       |               |              |              |             |
| Britannia Industries | BRIT.BO  | 1L     | 36,409        | 1,825.00     | 19.6        | 14.6        | 15.0          | 10.7       | 1.2%          | 27.3%        | 42.3%        | 52.3        |
| GSK Consumer         | GLSM.BO  | 1L     | 27,757        | 980.00       | 13.4        | 11.7        | 8.4           | 7.0        | 4.1%          | 31.7%        | 24.9%        | 16.2        |
| Nestle India         | NEST.BO  | 3L     | 136,433       | 1,341.00     | 29.1        | 25.1        | 16.4          | 14.2       | 2.6%          | 102.3%       | 189.5%       | 22.3        |
| Tata Tea             | TTTE.BO  | 1L     | 50,526        | 1,045.00     | 14.2        | 10.0        | 5.4           | 4.1        | 1.9%          | 52.9%        | 8.1%         | 26.9        |
| <b>Average</b>       |          |        |               |              | <b>19.1</b> | <b>15.3</b> | <b>11.3</b>   | <b>9.0</b> | <b>2.5%</b>   | <b>53.5%</b> | <b>66.2%</b> | <b>29.4</b> |

Source: Citi Investment Research

Figure 5. P/E 2009E versus 2 year EPS CAGR (2007-09E) of Indian F&B Companies



Source: Citi Investment Research

## Revising Estimates, Price Target

Following 9m07 results, we are tweaking our earnings model for Nestle and cutting our 2007E-09E EPS estimates by 6.9%-2.8%. Our earnings revision summary is enumerated below:

Figure 6. Earnings Revision Summary

|       | Net income (Rsm) |        |          | EPS (Rs) |      |          | DPS (Rs) |      |          |
|-------|------------------|--------|----------|----------|------|----------|----------|------|----------|
|       | Old              | New    | % Change | Old      | New  | % Change | Old      | New  | % Change |
| 2007E | 4318.0           | 4020.2 | -6.9     | 44.8     | 41.7 | -6.9     | 32.0     | 32.0 | 0.0      |
| 2008E | 5278.4           | 5175.2 | -2.0     | 54.8     | 53.7 | -2.0     | 36.0     | 36.0 | 0.0      |
| 2009E | 6190.1           | 6013.9 | -2.8     | 64.2     | 62.4 | -2.8     | 44.0     | 44.0 | 0.0      |

Source: Citi Investment Research

Despite cutting EPS estimates, we are increasing our target price to Rs1341 based on 25x08E P/E. Our increase in target price is based on the rolling forward of our target P/E multiple to end 2008, given that we are already approaching end-2007 and expect the stock valuations to start reflecting 2008 earnings.

## 3Q07 Results Tables

Figure 7. Nestle India 3Q 2007 Results Review (Rupees in Million, Percent)

|                               | 3QCY06         | 3QCY07         | %yoy            |
|-------------------------------|----------------|----------------|-----------------|
| <b>Net Sales</b>              | <b>7,226.6</b> | <b>9,067.4</b> | <b>25.5</b>     |
| Expenditure                   | -5,802.0       | -7,151.7       | 23.3            |
| <b>EBITDA</b>                 | <b>1,424.6</b> | <b>1,915.7</b> | <b>34.5</b>     |
| <i>EBITDA Margin (%)</i>      | <i>19.7</i>    | <i>21.1</i>    | <i>141 bps</i>  |
| Interest                      | -0.4           | -0.7           | 75.0            |
| Depreciation & Amortisation   | -167.9         | -184.3         | 9.8             |
| Other Income                  | 46.7           | 56.6           | 21.2            |
| <b>PBT</b>                    | <b>1,303.0</b> | <b>1,787.3</b> | <b>37.2</b>     |
| Tax                           | -431.2         | -597.3         | 38.5            |
| <i>Tax Rate (%)</i>           | <i>33.1</i>    | <i>33.4</i>    | <i>33 bps</i>   |
| <b>PAT</b>                    | <b>871.8</b>   | <b>1,190.0</b> | <b>36.5</b>     |
| Exceptional items             | -42.0          | -29.4          | -30.0           |
| <b>PAT after Exceptionals</b> | <b>829.8</b>   | <b>1,160.6</b> | <b>39.9</b>     |
| No of shares                  | 96.4           | 96.4           |                 |
| <b>EPS</b>                    | <b>8.6</b>     | <b>12.0</b>    |                 |
| <b>Cost Details</b>           |                |                |                 |
| Total Raw Material Cost       | 3,402.2        | 4,329.3        | 27.3            |
| <i>% of Sales</i>             | <i>47.1</i>    | <i>47.7</i>    | <i>67 bps</i>   |
| Employee/Staff Cost           | 538.9          | 692.6          | 28.5            |
| <i>% of Sales</i>             | <i>7.5</i>     | <i>7.6</i>     | <i>18 bps</i>   |
| Other Expenditure             | 1,860.9        | 2,129.8        | 14.4            |
| <i>% of Sales</i>             | <i>25.8</i>    | <i>23.5</i>    | <i>-226 bps</i> |

Source: Company Reports

## Nestle India

### Company description

Nestle India, a 57% subsidiary of Nestle SA, is the largest and most diversified food and beverage company in India. The group has a dominant market position in infant food, cereals, and instant coffee and culinary products, and is No.2 in the chocolate market. Its product portfolio comprises some of Nestlé's best-known global brands — Nescafe, Lactogen, Cerelac, Maggi and Kit Kat. The company has a strong focus on adding value to basic commodities, and has an extensive distribution network, covering most of the urban and semi-urban areas.

### Investment strategy

We have a Sell/Low Risk rating on Nestle, which we recently revised from a Buy (1L). While Nestle is the best play on urban consumption growth in the Indian consumer sector universe, and has grown much ahead of the consumer sector growth average, its valuations are capturing this growth premium. The stock is currently trading at the higher end of its historic valuation multiples, and we do not see any further re-rating triggers. Historically, Nestle has benefited on two counts – on the demand side from its urban exposure, which was driven by high service sector growth, and on the costs side through its agri-product

exposure, where raw-material prices remained soft over a long period. However, over the last 2 years, raw material costs have been firming up, which has put pressure on margins. While Nestle has been able to mitigate margin pressure through price hikes, we believe that if raw material costs keep firming up, it will be difficult to hike prices without sacrificing volumes.

## Valuation

Nestle is a steady growth company, and hence P/E in relation to expected growth appears best suited to value it. We believe Nestle India should trade at Rs1341, based on 25x Dec08E P/E - at the midpoint of its recent trading bands. At 25x P/E, Nestle would trade at almost 25% premium to Sensex P/E, which we believe is sustainable given its better relative earnings profile and significantly higher capital efficiency ratios (close to 100% ROE). On an EV/EBITDA basis, Nestle could trade between 15x-18x, a significant premium to the Sensex as the company enjoys strong cash flows as well as among the highest capital-efficiency ratios. Our price target of Rs1341 implies an EV/EBITDA of about 15x Dec-08E.

## Risks

We rate Nestle Low Risk based on our quantitative models. The key downside risks to our target price include: (1) fluctuations in commodity prices could affect profitability prospects; (2) Nestle may not gain significantly in an economic recovery led by the rural sector given its high urban exposure; and (3) supply constraints on raw materials, particularly milk solids, could stifle growth. The key upside risks to our target price include: (1) better-than-expected sales growth performance; (2) favorable agri-product prices; and (3) any fiscal benefits offered by the government to the food processing industry.

## Britannia Industries (BRIT.BO - Rs1,518.00; 1L)

### Valuation

At current valuations we rate the Britannia Buy (1L). Our Rs1,825 target price is based on 20x mid-FY09E P/E, at the higher end of its recent trading band. Our target P/E reflects new top management appointments that should quell corporate governance concerns and ensure strong business growth, as well as recent resurgence in sales growth and margins. We expect a 42% EPS CAGR over FY07-10E. At 20x mid-FY09E P/E, Britannia would trade at a 20% premium to the market average P/E. We use P/E as our base valuation methodology, as Britannia has steady earnings growth. At our target price, the stock would trade at 15x 12-month forward EV/EBITDA, which is at about 20% premium to the average market multiple.

### Risks

We rate Britannia Low Risk based on our quantitative risk-rating system, which tracks 260-day share price volatility. The key downside risks that could impede the stock from reaching our target price are: 1) continuation of the inflationary

trends in raw-material prices, which could put further pressure on margins; 2) slowing demand resulting in poor top-line growth; 3) and increased competitive intensity, which could restrain pricing power. The key upside risks that could prevent the shares attaining our target are: further pick-up in volume growth on the back of resurgence in rural demand; rationalization of competition allowing for price increases in biscuits especially in the high volume glucose biscuits where prices have not seen increases in the last three years; a potential stake sale by the Wadias to Danone International which along with the Wadias is an equal majority stake holder in Britannia; turn in the agri-commodity price trend which could mitigate raw-material cost pressure.

## **GlaxoSmithKline Consumer (GLSM.BO - Rs665.00; 1L)**

### **Valuation**

GSK Consumer is likely to have steady growth in earnings despite some minor hiccups in the past 24 months, and we believe P/E is best suited to value the company. Our target price of Rs980 is based on 20x CY08E P/E. The stock has historically traded at a range of 12x to 21x, with an average of about 15x, over the past seven years. We feel a 20x multiple is warranted given relatively better earnings profile and higher capital-efficiency ratios. It currently has the lowest PE among our Indian consumer universe and above average EPS growth, which makes it an attractive buy, in our view. A higher dividend payout is likely to help stock valuations and should provide downside support.

### **Risks**

We rate GSK as Low Risk because the company operates in a branded segment in which earnings visibility is high and earnings follow a secular trend. The key downside risks to our target price include: (1) the re-launch of Horlicks could confuse users and lead to brand switches; (2) a rural recovery may not fully manifest into additional sales for GSK; and (3) competition.

## **Tata Tea (TTTE.BO - Rs821.45; 1L)**

### **Valuation**

Our target price for Tata Tea shares is Rs1,045 based on 15x mid-FY09E P/E. We use P/E as our primary valuation tool given the steady state of the business and no major changes in the investment profile. We believe Tata Tea's stock warrants a re-rating due to a pickup in growth and margins for its domestic business, and given that it has reduced its commodity linkages with 88% of its global business now being branded. Our target multiple is at par with the market P/E, which we believe is justified given these factors.

We have also valued Tata Tea on an EV/EBITDA basis. Our target price pegs the stock at 11-12x mid-FY09E EV/EBITDA, in line with our implied target multiple for the market taking into consideration the above factors.



## **Risks**

We rate Tata Tea shares Low Risk given the steady state of the business and no major changes in the investment profile. The key downside risks that could prevent the shares from reaching our target price include: (1) declines in domestic tea prices, and/or increases in international prices; (2) appreciation of the INR vs. the GBP; (3) a slowdown in domestic market sales; and (4) investing in Tetley brands in new markets like Pakistan and Bangladesh.

# Appendix A-1

## Analyst Certification


Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research associate in this research report.

## IMPORTANT DISCLOSURES

### Britannia Industries (BRIT.BO)

#### Ratings and Target Price History - Fundamental Research

Analyst: Princy Singh



| #  | Date      | Rating | Target Price | Closing Price |
|----|-----------|--------|--------------|---------------|
| 1: | 21 Dec 04 | 1L     | *1,100.00    | 888.20        |
| 2: | 9 Nov 05  | 1L     | *1,480.00    | 1,249.90      |
| 3: | 31 Jan 06 | 1L     | *1,720.00    | 1,459.95      |
| 4: | 5 May 06  | *3L    | 1,720.00     | 1,775.00      |
| 5: | 19 Jun 06 | *1L    | 1,720.00     | 1,319.80      |
| 6: | 1 Jun 07  | 1L     | *1,825.00    | 1,538.65      |

\*Indicates change.

### GlaxoSmithKline Consumer (GLSM.BO)

#### Ratings and Target Price History - Fundamental Research

Analyst: Princy Singh



| #  | Date      | Rating | Target Price | Closing Price |
|----|-----------|--------|--------------|---------------|
| 1: | 2 May 05  | 1L     | *395.00      | 341.35        |
| 2: | 25 Jul 05 | 1L     | *500.00      | 434.80        |
| 3: | 21 Oct 05 | 1L     | *540.00      | 478.35        |
| 4: | 31 Jan 06 | 1L     | *725.00      | 607.75        |
| 5: | 1 Feb 07  | 1L     | *675.00      | 582.60        |
| 6: | 26 Jul 07 | 1L     | *770.00      | 574.15        |
| 7: | 24 Oct 07 | 1L     | *980.00      | 665.45        |

\*Indicates change.

## Nestle India (NEST.BO)

31 October 2007

### Nestle India (NEST.BO)

#### Ratings and Target Price History - Fundamental Research

Analyst: Princy Singh



| #  | Date      | Rating | Target Price | Closing Price |
|----|-----------|--------|--------------|---------------|
| 1: | 15 Mar 05 | *1L    | *710.00      | 637.35        |
| 2: | 2 Aug 05  | *3L    | *776.00      | 804.95        |
| 3: | 30 Nov 06 | 3L     | *916.00      | 1,093.50      |
| 4: | 2 May 07  | *1L    | *1,244.00    | NA            |

\*Indicates change.

### Tata Tea (TTTE.BO)

#### Ratings and Target Price History - Fundamental Research

Analyst: Princy Singh



| #  | Date      | Rating | Target Price | Closing Price |
|----|-----------|--------|--------------|---------------|
| 1: | 4 Jan 05  | 3L     | *412.00      | 499.85        |
| 2: | 26 Jul 05 | 3L     | *500.00      | 671.20        |
| 3: | 8 Feb 06  | 3L     | *680.00      | 928.55        |
| 4: | 19 Jun 06 | *1L    | *960.00      | 699.35        |
| 5: | 27 May 07 | 1L     | *1,150.00    | 934.10        |
| 6: | 18 Jul 07 | 1L     | *1,045.00    | 782.45        |

\*Indicates change.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Britannia Industries. This position reflects information available as of the prior business day.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from GlaxoSmithKline Consumer and Nestle India.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Britannia Industries, GlaxoSmithKline Consumer, Nestle India and Tata Tea in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): GlaxoSmithKline Consumer and Nestle India.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Britannia Industries, GlaxoSmithKline Consumer, Nestle India and Tata Tea.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Britannia Industries, GlaxoSmithKline Consumer, Nestle India and Tata Tea.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at [www.citigroupgeo.com](http://www.citigroupgeo.com). Private Client Division clients should refer to [www.smithbarney.com/research](http://www.smithbarney.com/research). Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

#### Citi Investment Research Ratings Distribution

Data current as of 30 September 2007

|   | Buy | Hold | Sell |
|---|-----|------|------|
| Citi Investment Research Global Fundamental Coverage (3358) | 50% | 38%  | 12%  |

---

*% of companies in each rating category that are investment banking clients*

53%

55%

42%

---

**Guide to Fundamental Research Investment Ratings:**

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

**Risk ratings**, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

**Investment ratings** are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

---

**Guide to Corporate Bond Research Credit Opinions and Investment Ratings:**

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at <http://sd.ny.ssm.com/> using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underperform the relevant sector of the Citigroup indexes.

---

**OTHER DISCLOSURES**

The subject company's share price set out on the front page of this Product is quoted as at 31 October 2007 04:00 PM on the issuer's primary market.

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Britannia Industries.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

This Product has been modified by the author following a discussion with one or more of the named companies.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

---

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at [www.citigroupgeo.com](http://www.citigroupgeo.com). Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

---

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

---

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

---